Long-term Outcomes in Patients with Primary Biliary Cholangitis Complicated with CREST Syndrome

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 19

PMID 38898064

Authors

Kazumichi Abe

Manabu Hayashi

Tatsuro Sugaya

Naoto Abe

Yosuke Takahata

Masashi Fujita

Atsushi Takahashi

Kiyoshi Migita

Hiromasa Ohira

Affiliations

Soon will be listed here.

Abstract

Primary biliary cholangitis (PBC) is frequently associated with autoimmune disease. Although PBC complicated with CREST syndrome (PBC-CREST) has been reported, the long-term outcomes of the affected patients have not been fully investigated. Herein, the long-term outcomes of PBC-CREST were evaluated. Next, the GLOBE and UK-PBC scores were validated and compared between the PBC alone and PBC-CREST groups. A total of 302 patients who were diagnosed with PBC between December 1990 and August 2021 at Fukushima Medical University Hospital were included. The liver transplantation (LT)-free survival rates were compared between patients with PBC alone (n = 245) and those with PBC-CREST (n = 57). Moreover, 173 patients, excluding those with liver-related death/LT within 1 year after ursodeoxycholic acid administration, were divided into two subgroups (PBC alone (n = 147) and PBC-CREST (n = 26)), and the GLOBE and UK-PBC scores were compared between the subgroups. The survival rates without LT (3/5/10 years) were 92/87/80% for the PBC-alone group and 98/96/96% for the PBC-CREST group, with a significantly better prognosis in the PBC-CREST group (log-rank P = 0.0172). Multivariate analysis revealed that the presence of CREST syndrome is an independent protective factor for the presence of cirrhosis. The predicted 5/10/15-year risks of liver-related death or LT based on the UK-PBC score were significantly lower in the PBC-CREST group (2.4/7.6/13.2%) than in the PBC-alone group (4.8/11.8/18.8%) (P < 0.05). The predicted 3/5-year LT-free survival rates based on the GLOBE score were significantly higher in the PBC-CREST group (93/88%) than in the PBC-alone group (88/81%) (P < 0.05). Patients with PBC-CREST may have better long-term outcomes than those with PBC alone.

References

Lindor K, Gershwin M, Poupon R, Kaplan M, Bergasa N, Heathcote E . Primary biliary cirrhosis. Hepatology. 2009; 50(1):291-308. DOI: 10.1002/hep.22906. View

Reynolds T, Denison E, FRANKL H, Lieberman F, Peters R . Primary biliary cirrhosis with scleroderma, Raynaud's phenomenon and telangiectasia. New syndrome. Am J Med. 1971; 50(3):302-12. DOI: 10.1016/0002-9343(71)90218-x. View

Powell F, Schroeter A, Dickson E . Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases. Q J Med. 1987; 62(237):75-82. View

Cheung A, Gulamhusein A, Juran B, Schlicht E, McCauley B, de Andrade M . External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Hepatol Commun. 2018; 2(6):676-682. PMC: 5983113. DOI: 10.1002/hep4.1186. View

Lammers W, Hirschfield G, Corpechot C, Nevens F, Lindor K, Janssen H . Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015; 149(7):1804-1812.e4. DOI: 10.1053/j.gastro.2015.07.061. View

Cameron A, Malcolm A, Prather C, Phillips S . Videoendoscopic diagnosis of esophageal motility disorders. Gastrointest Endosc. 1998; 49(1):62-9. DOI: 10.1016/s0016-5107(99)70447-5. View

Fregeau D, Leung P, Coppel R, McNeilage L, Medsger Jr T, Gershwin M . Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum. 1988; 31(3):386-92. DOI: 10.1002/art.1780310310. View

Lepri G, Bellando Randone S, Cerinic M, Allanore Y . Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. J Scleroderma Relat Disord. 2022; 4(2):111-117. PMC: 8922650. DOI: 10.1177/2397198318802763. View

Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M . Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. Hepatology. 2019; 70(6):2035-2046. DOI: 10.1002/hep.30552. View

10.

Shoji I, Takagi T, Kasukawa R . Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med. 1992; 31(12):1348-55. DOI: 10.2169/internalmedicine.31.1348. View

11.

Poupon R, Balkau B, Eschwege E, Poupon R . A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991; 324(22):1548-54. DOI: 10.1056/NEJM199105303242204. View

12.

Kuribayashi S, Hosaka H, Uraoka T . Usefulness of Endoscopy for the Detection and Diagnosis of Primary Esophageal Motility Disorders and Diseases Relating to Abnormal Esophageal Motility. Diagnostics (Basel). 2023; 13(4). PMC: 9955791. DOI: 10.3390/diagnostics13040695. View

13.

Carbone M, Sharp S, Flack S, Paximadas D, Spiess K, Adgey C . The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2015; 63(3):930-50. PMC: 6984963. DOI: 10.1002/hep.28017. View

14.

You H, Ma X, Efe C, Wang G, Jeong S, Abe K . APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int. 2022; 16(1):1-23. PMC: 8843914. DOI: 10.1007/s12072-021-10276-6. View

15.

McMahan Z, Kulkarni S, Chen J, Chen J, Xavier R, Pasricha P . Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol. 2023; 19(3):166-181. DOI: 10.1038/s41584-022-00900-6. View

16.

Imura-Kumada S, Hasegawa M, Matsushita T, Hamaguchi Y, Encabo S, Shums Z . High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Mod Rheumatol. 2012; 22(6):892-8. DOI: 10.1007/s10165-012-0607-z. View

17.

Watt F, James O, Jones D . Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004; 97(7):397-406. DOI: 10.1093/qjmed/hch078. View

18.

Rigamonti C, Shand L, Feudjo M, Bunn C, Black C, Denton C . Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut. 2005; 55(3):388-94. PMC: 1856066. DOI: 10.1136/gut.2005.075002. View

19.

Assassi S, Fritzler M, Arnett F, Norman G, Shah K, Gourh P . Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol. 2009; 36(10):2250-6. PMC: 2885441. DOI: 10.3899/jrheum.090340. View

20.

Ding D, Guo G, Liu Y, Zheng L, Jia G, Deng J . Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid. Hepatol Commun. 2022; 6(12):3487-3495. PMC: 9701475. DOI: 10.1002/hep4.2103. View